Details

Autor(en) / Beteiligte

• Loomba, Rohit
• Seguritan, Victor
• Li, Weizhong
• Long, Tao
• Klitgord, Niels
• Bhatt, Archana
• Dulai, Parambir Singh
• Caussy, Cyrielle
• Bettencourt, Richele
• Highlander, Sarah K.
• Jones, Marcus B.
• Sirlin, Claude B.
• Schnabl, Bernd
• Brinkac, Lauren
• Schork, Nicholas
• Chen, Chi-Hua
• Brenner, David A.
• Biggs, William
• Yooseph, Shibu
• Venter, J. Craig
• Nelson, Karen E.

Titel

Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease

Ist Teil von

• Cell metabolism, 2017-05, Vol.25 (5), p.1054-1062.e5

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• The presence of advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is the most important predictor of liver mortality. There are limited data on the diagnostic accuracy of gut microbiota-derived signature for predicting the presence of advanced fibrosis. In this prospective study, we characterized the gut microbiome compositions using whole-genome shotgun sequencing of DNA extracted from stool samples. This study included 86 uniquely well-characterized patients with biopsy-proven NAFLD, of which 72 had mild/moderate (stage 0–2 fibrosis) NAFLD, and 14 had advanced fibrosis (stage 3 or 4 fibrosis). We identified a set of 40 features (p < 0.006), which included 37 bacterial species that were used to construct a Random Forest classifier model to distinguish mild/moderate NAFLD from advanced fibrosis. The model had a robust diagnostic accuracy (AUC 0.936) for detecting advanced fibrosis. This study provides preliminary evidence for a fecal-microbiome-derived metagenomic signature to detect advanced fibrosis in NAFLD. [Display omitted] •Gut microbiota is associated with advanced fibrosis in human NAFLD•Metagenome-based gut microbiome panel can accurately diagnose advanced fibrosis Loomba et al. reveal how a panel of gut microbiome biomarkers can be used as a non-invasive test to accurately diagnose advanced fibrosis in patients with non-alcoholic fatty liver disease.